Research programme: RAD51 modulators - Cyteir Therapeutics

Drug Profile

Research programme: RAD51 modulators - Cyteir Therapeutics

Alternative Names: RAD51-AID

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyteir Therapeutics
  • Class Antihyperglycaemics; Antineoplastics
  • Mechanism of Action Rad51 recombinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; B cell lymphoma; Leukaemia; Type 1 diabetes mellitus

Most Recent Events

  • 08 Mar 2018 Preclinical trials in Autoimmune disorders in USA (Parenteral) before March 2018
  • 08 Mar 2018 Cyteir Therapeutics plans a clinical trial for Cancer in 2019
  • 01 Jun 2017 Preclinical trials in Type-1 diabetes mellitus in USA before June 2017 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top